Skip to main content
. 2018 Mar 22;103(6):1029–1037. doi: 10.3324/haematol.2017.186528

Figure 5.

Figure 5.

MYD88L265P can be used for disease monitoring. MYD88L265P monitored in 52 patients with at least one follow-up (FU) sample. ctDNA: cell tumor DNA; RE: relapsed at baseline; NT: Naïve to Treatment at baseline; MRD: minimal residual disease; PL: plasma; BM: bone marrow; PB: peripheral blood.